Catalent Applied Drug Delivery Institute Appoints Jim Spavins to Advisory Board

The Catalent Applied Drug Delivery Institute announced Jim Spavins has joined the Institute’s Advisory Board. Spavins brings over 36 years of industry and academic experience to the Institute, having previously worked at all levels of research and development, reaching the position of Senior Vice President of Pfizer's Global Pharma Therapeutics Pharmaceutical Sciences group before starting his own consulting business, Spavins Consulting.

“I look forward to working with the CADDI Board to help rapidly advance innovative drug delivery solutions to patients,” Spavins said. “There has never been a more exciting time to leverage astonishing scientific advances in disease understanding with optimum delivery technology.”

“I’m very pleased to welcome Jim to the Institute,” Dr. Cornell Stamoran, Founder of the Catalent Applied Drug Delivery Institute and Catalent’s VP Strategy said. “He brings us a wealth of scientific and leadership experience, front line exposure to translational drug delivery, and a strong passion to enhance patient focus during drug development.”

Spavins has worked across large and small R&D groups within all the technical disciplines of chemistry, manufacturing and controls (CMC) development, as well as regulatory, quality, clinical supply, commercial manufacture, and economic analysis. His successful development projects have included in-house discovery programs, as well as working with small start-ups to bring licensed or acquired programs through development. Spavins has broad experience with of a wide network of contract development and manufacturing organizations (CDMOs) and other partners to advance programs.

Spavins holds a bachelor’s degree in chemistry from Queens College, New York, as well as a Master of Arts degree in analytical chemistry, and a Master of Science degree in chemical engineering, both from University of Buffalo, New York.

  • <<
  • >>

Join the Discussion